Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.

IF 5.5 3区医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-05-02 DOI:10.1080/14760584.2024.2345670

Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna Perdrizet, Kazumasa Kamei

{"title":"Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.","authors":"Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna Perdrizet, Kazumasa Kamei","doi":"10.1080/14760584.2024.2345670","DOIUrl":null,"url":null,"abstract":"Background: The Japanese National Immunization Program currently includes the pediatric 13 valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13.Methods: A decision-analytic Markov model was used to estimate expected costs, quality-adjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives.Results: PCV20 was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced Japanese yen [JPY] 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition cost of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective).Conclusions: As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2345670","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Japanese National Immunization Program currently includes the pediatric 13 valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pediatric vaccine versus PCV13.

Methods: A decision-analytic Markov model was used to estimate expected costs, quality-adjusted life-years (QALYs), and prevented cases and deaths caused by invasive pneumococcal disease, pneumonia, and acute otitis media over a ten-year time horizon from the societal and healthcare payer perspectives.

Results: PCV20 was dominant, i.e. less costly and more effective, over PCV13 (gained 294,599 QALYs and reduced Japanese yen [JPY] 352.6 billion [2.6 billion United States dollars, USD] from the societal perspective and JPY 178.9 billion [USD 1.4 billion] from the payer perspective). Sensitivity and scenario analyses validated the robustness of the base scenario results. When comparing PCV20 with PCV13, the threshold analysis revealed an incremental cost-effectiveness ratio that was within the threshold value (JPY 5 million/QALY) at a maximum acquisition cost of JPY 74,033 [USD 563] (societal perspective) and JPY 67,758 [USD 515] (payer perspective).

Conclusions: As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

日本常规儿科疫苗接种计划中 20 价肺炎球菌结合疫苗的成本效益分析。

背景：日本国家免疫计划目前包括预防肺炎球菌感染的儿科 13 价肺炎球菌结合疫苗 (PCV13)。我们旨在评估 20 价 PCV（PCV20）作为儿科疫苗与 PCV13 相比的成本效益：方法：我们使用决策分析马尔可夫模型，从社会和医疗支付方的角度估算了十年内侵袭性肺炎球菌病、肺炎和急性中耳炎的预期成本、质量调整生命年 (QALY) 以及预防病例和死亡人数：PCV20 比 PCV13 更具优势，即成本更低且更有效（从社会角度看，PCV20 获得了 294,599 QALYs，减少了 3,526 亿日元[26 亿美元]；从支付方角度看，PCV20 减少了 1,789 亿日元[14 亿美元]）。敏感性和情景分析验证了基本情景结果的稳健性。在对 PCV20 和 PCV13 进行比较时，阈值分析显示，在最大获得成本为 74,033 日元 [563 美元] （社会角度）和 67,758 日元 [515 美元] （支付方角度）时，增量成本效益比在阈值（500 万日元/QALY）范围内：结论：作为儿科疫苗，无论从哪个角度进行研究，PCV20 都比 PCV13 占优。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.